Karolinska Development appoints Klaus Wilgenbus as interim chief executive

Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief executive on an interim basis, following the departure of Torbjörn Bjerke from the position.

The search for a permanent chief executive has been initiated, but until then Klaus Wilgenbus, member of Karolinska’s board since 2012 will be acting chief executive.

Dr Wilgenbus is an independent healthcare analyst and consultant with a history as a senior leader in drug discovery, deal-making, corporate strategy and restructuring of research of development. He recently left Boehringer Ingelheim after 18 years in different management positions.